Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 705Carcinoma, Non-Small-Cell Lung 472Prostatic Neoplasms 420Neoplasms 379Multiple Myeloma 261Colorectal Neoplasms 261Lung Neoplasms 248Neoplasm Metastasis 230Melanoma 215Ovarian Neoplasms 191Leukemia, Myeloid, Acute 190Pancreatic Neoplasms 181Squamous Cell Carcinoma of Head and Neck 163Recurrence 146Carcinoma, Renal Cell 144Lymphoma 142Glioblastoma 138Lymphoma, Non-Hodgkin 134Stomach Neoplasms 129Triple Negative Breast Neoplasms 127Carcinoma, Hepatocellular 123Brain Neoplasms 123Leukemia, Lymphocytic, Chronic, B-Cell 122Uterine Cervical Neoplasms 117Head and Neck Neoplasms 117Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Urinary Bladder Neoplasms 113Lymphoma, Large B-Cell, Diffuse 105Sarcoma 102Lymphoma, Follicular 100

Interventions

ixabepilone 1Standard of Care 1Practice Guidelines as Topic 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Bilateral Breast Carcinoma × Clear all
NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡